Te Ahumairangi Investment Management Ltd Has $1.87 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Te Ahumairangi Investment Management Ltd decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 158,011 shares of the company’s stock after selling 43,601 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in Roivant Sciences were worth $1,869,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ROIV. GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. increased its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after acquiring an additional 1,507 shares during the period. Quarry LP raised its stake in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the last quarter. Blue Trust Inc. boosted its holdings in Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after purchasing an additional 6,667 shares during the period. Finally, HighTower Advisors LLC acquired a new stake in Roivant Sciences in the 4th quarter worth $121,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,395,541 shares of company stock valued at $15,028,538. 7.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.10.

Roivant Sciences Stock Down 2.4 %

Shares of ROIV opened at $9.85 on Wednesday. The company has a 50-day moving average price of $10.69 and a two-hundred day moving average price of $11.37. The stock has a market cap of $7.03 billion, a price-to-earnings ratio of -65.66 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.